Please assess the completion status of the following clinical trial:

Trial Title: Sandostatin for Patients With Androgen Independent Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the prostate.~* Biochemical disease progression following androgen deprivation and therapy with at least one antiandrogen defined as three rises in PSA with PSA determinations at least 4 weeks apart and each PSA value \> 0.2 ng/ml.~* Four weeks since prior therapy with Flutamide.~* Six weeks since prior therapy with Bicalutamide or Nilutamide.~* Current PSA \> 5 ng/ml.~* Testosterone \<50 ng/dL.~* SGPT (ALT) \< 1.5 times upper limit of normal.~* Fasting blood glucose \> 60 mg/dL.~* ECOG performance status 0, 1 or 2.~* No visceral or bony metastatic disease (Lymph node only metastases are allowed).~* No prior chemotherapy for prostate cancer.~* No current treatment with insulin or an oral hypoglycemic.~* No history of treatment with octreotide analogs for prostate cancer.~* No NYHA Class 3 or 4 cardiac status.~Exclusion Criteria:~* Diabetes Mellitus requiring medical therapy and/or that which is not controlled by dietary means (HbA1C\<6.0).~* A history of gallstones that has been clinically significant. Patients who have undergone cholecystectomy are eligible.~* Other concomitant medical or psychiatric condition which would make it undesirable, in the physician's opinion, for the patient to participate in the protocol or would jeopardize compliance with the protocol requirements.~* Prior treatment with chemotherapy for prostate cancer.~* No current treatment with Saw Palmetto, or Proscar. Patients must be off these medicines for more than 4 weeks.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).